Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3
about
Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competitionMechanisms of vancomycin resistance in Staphylococcus aureusMolecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureusDissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.Mutation landscape of acquired cross-resistance to glycopeptide and β-lactam antibiotics in Enterococcus faeciumGenomic, Transcriptomic and Metabolomic Studies of Two Well-Characterized, Laboratory-Derived Vancomycin-Intermediate Staphylococcus aureus Strains Derived from the Same Parent Strain.Genome sequence-based discriminator for vancomycin-intermediate Staphylococcus aureus.Glycopeptide antibiotics: back to the future.Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.Prevalence of Slow-growth Vancomycin Non-susceptibility In Methicillin-resistant Staphylococcus aureus.Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental StrainComplete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureusPhenotypic and genomic comparisons of highly vancomycin-resistant Staphylococcus aureus strains developed from multiple clinical MRSA strains by in vitro mutagenesis.A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA"In Vitro Tolerance of Drug-Naive Staphylococcus aureus Strain FDA209P to Vancomycin."Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility.
P2860
Q24490083-750B961A-3761-4D8E-AB39-9BD6D0ED86D1Q26829312-51D779D6-B133-4D57-86FF-95BF636AF418Q28078930-69F7CDE6-51C8-422C-9F0D-C6EC452C0A66Q33696380-17D1A113-F96B-44C5-8E79-DBCE904D1EC8Q35960716-B130D258-BAE2-441B-BFA7-34AAD5211AD3Q36683542-CCB1C57B-233B-4B83-BF6E-A6F8A068BF77Q37643403-10B7470D-0760-4FBA-A9D6-E5086292BD61Q38239460-7BEC89F5-57CD-4ADB-8237-055193FE60A5Q38728885-5AAE945E-6F6F-46A4-A4F4-5779FC559A2AQ40085144-A5081EE2-25C9-48A3-A29A-1732ED1898A4Q40404574-A59559A2-05E1-4FB0-9EB4-CE80DC2549A4Q40719288-6B482FEC-69C4-4951-B7D3-25A94A539D45Q40896611-822B3985-BC80-43F1-BFB9-FB2811A68435Q41259277-DCBA4DD4-4CC0-4344-B71E-5AF920626433Q41921688-13A5B5F2-0BB7-4F7D-B6F4-A39ABCBCDE26Q42109713-70C973E7-411C-4DBA-83B1-B1BB1C2A3A22Q50132676-9923B225-321F-4E87-A22E-7BC2186E7624Q55014868-C21B338A-815E-4EA7-BF80-E0F5AFC09EB6
P2860
Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comprehensive identification o ...... from hVISA clinical strain Mu3
@en
Comprehensive identification o ...... rmediate Staphylococcus aureus
@nl
type
label
Comprehensive identification o ...... from hVISA clinical strain Mu3
@en
Comprehensive identification o ...... rmediate Staphylococcus aureus
@nl
prefLabel
Comprehensive identification o ...... from hVISA clinical strain Mu3
@en
Comprehensive identification o ...... rmediate Staphylococcus aureus
@nl
P2093
P2860
P356
P1476
Comprehensive identification o ...... from hVISA clinical strain Mu3
@en
P2093
Jeeyoung Kim
Keiichi Hiramatsu
Longzhu Cui
Miki Matsuo
P2860
P304
P356
10.1128/AAC.00425-13
P407
P577
2013-09-09T00:00:00Z